/COGT
COGT Stock - Cogent Biosciences, Inc.
Healthcare|BiotechnologyNASDAQ
$39.55+4.35%
+$1.65 (+4.35%) • Dec 19
74
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).54
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+2.1%upside
Target: $40.38
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for COGT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$39.15 – $39.95
TARGET (TP)$40.40
STOP LOSS$36.39
RISK/REWARD1:0.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.51
52W High$43.73
52W Low$3.72
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $7.87M |
| Gross Profit | N/A | N/A | N/A | N/A | $-17,867,000 |
| Gross Margin | N/A | N/A | N/A | N/A | -227.0% |
| Operating Income | $-275,939,000 | $-208,130,000 | $-147,839,000 | $-75,551,000 | $-82,199,000 |
| Net Income | $-255,859,000 | $-192,410,000 | $-140,241,000 | $-72,273,000 | $-74,808,000 |
| Net Margin | N/A | N/A | N/A | N/A | -950.4% |
| EPS | $-2.46 | $-2.42 | $-2.26 | $-1.85 | $-6.00 |
Company Overview
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
1
8%
Buy / Outperform
8
62%
Hold / Neutral
4
31%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
9 Bullish4 Neutral/Bearish
Price Targets
$21
Average Target
↓ 47.5% Downside
Now
$5
Low
$21
Average
$40
High
Based on 13 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 10th 2025 | Stifel | Upgrade | Buy | $40 |
| November 10th 2025 | Wedbush | Upgrade | Outperform | $38 |
| October 16th 2025 | Stifel | Initiation | Hold | $16 |
| September 3rd 2025 | Raymond James | Initiation | Strong Buy | $30 |
| March 7th 2025 | Scotiabank | Initiation | Sector Outperform | $17 |
| December 11th 2024 | Needham | Downgrade | Hold | - |
| February 26th 2024 | Robert W. Baird | Downgrade | Neutral | $8← $14 |
| February 8th 2024 | Citigroup | Initiation | Buy | $11 |
| December 11th 2023 | Wedbush | Downgrade | Neutral | $5 |
| December 8th 2023 | JP Morgan | Initiation | Overweight | $18 |
| April 28th 2023 | Robert W. Baird | Initiation | Outperform | $20 |
| March 27th 2023 | H.C. Wainwright | Resumed | Buy | $28 |
| December 14th 2022 | Needham | Initiation | Buy | $24 |
| June 28th 2022 | Guggenheim | Initiation | Buy | $15 |
Earnings History & Surprises
COGTBeat Rate
33%
Last 18 quarters
Avg Surprise
-4.2%
EPS vs Estimate
Beats / Misses
6/12
Last 12 quarters
Latest EPS
$-0.50
Q4 2025
EPS Surprise History
Q1 24
-16.7%
$-0.63vs$-0.54
Q2 24
-24.0%
$-0.62vs$-0.50
Q3 24
-7.3%
$-0.59vs$-0.55
Q4 24
-16.4%
$-0.64vs$-0.55
Q1 25
+84.7%
$-0.09vs$-0.59
Q2 25
+7.1%
$-0.52vs$-0.56
Q3 25
+3.6%
$-0.53vs$-0.55
Q4 25
+7.4%
$-0.50vs$-0.54
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 24, 2026 | $-0.51 | — | — | — |
Q4 2025 | Nov 7, 2025 | $-0.54 | $-0.50 | +7.4% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $-0.55 | $-0.53 | +3.6% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-0.56 | $-0.52 | +7.1% | ✓ BEAT |
Q1 2025 | Feb 25, 2025 | $-0.59 | $-0.09 | +84.7% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.55 | $-0.64 | -16.4% | ✗ MISS |
Q3 2024 | Aug 6, 2024 | $-0.55 | $-0.59 | -7.3% | ✗ MISS |
Q2 2024 | May 7, 2024 | $-0.50 | $-0.62 | -24.0% | ✗ MISS |
Q1 2024 | Feb 26, 2024 | $-0.54 | $-0.63 | -16.7% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-0.50 | $-0.64 | -28.0% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-0.53 | $-0.59 | -11.3% | ✗ MISS |
Q2 2023 | May 9, 2023 | $-0.58 | $-0.54 | +6.9% | ✓ BEAT |
Q1 2023 | Mar 14, 2023 | $-0.50 | $-0.56 | -12.0% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.51 | $-0.50 | +2.0% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.64 | $-0.71 | -10.9% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-0.53 | $-0.68 | -28.3% | ✗ MISS |
Q1 2022 | Mar 15, 2022 | $-0.55 | $-0.61 | -10.9% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.43 | $-0.48 | -11.6% | ✗ MISS |
Q3 2021 | Aug 16, 2021 | $-0.39 | $-0.43 | -10.3% | ✗ MISS |
Latest News
JP Morgan Maintains Overweight on Cogent Biosciences, Raises Price Target to $67
📈 PositiveBenzinga•Dec 19, 2025, 04:27 PM
Needham Reiterates Hold on Cogent Biosciencesto Hold
➖ NeutralBenzinga•Dec 8, 2025, 04:17 PM
Cogent Biosciences shares are trading higher after the company reported positive APEX trial results for bezuclastinib in advanced systemic mastocytosis.
📈 PositiveBenzinga•Dec 8, 2025, 12:49 PM
Cogent Biosciences Reports APEX Trial Results for Bezuclastinib in Advanced Systemic Mastocytosis
➖ NeutralBenzinga•Dec 8, 2025, 12:37 PM
Reported Saturday, Cogent Biosciences Highlights Bezuclastinib Rapid, Deep, Sustained Improvement In Objective Measures Of Mast Cell Burden In SUMMIT NonAdvSM Study
📈 PositiveBenzinga•Dec 8, 2025, 09:06 AM
HC Wainwright & Co. Maintains Buy on Cogent Biosciences, Raises Price Target to $50
📈 PositiveBenzinga•Nov 13, 2025, 12:57 PM
Reported Earlier, Cogent Biosciences Announces Pricing Of Public Offerings Of 9.68M Shares At $31 Each And $200M 1.625% Convertible Senior Notes Due 2031 Raising $475.3M
➖ NeutralBenzinga•Nov 12, 2025, 07:04 AM•Also:
Baird Maintains Neutral on Cogent Biosciences, Raises Price Target to $34
➖ NeutralBenzinga•Nov 11, 2025, 01:12 PM
Leerink Partners Maintains Outperform on Cogent Biosciences, Raises Price Target to $50
📈 PositiveBenzinga•Nov 10, 2025, 09:21 PM
Cogent Biosciences Announces $200M Senior Notes Offering, $200M Common Stock Offering
➖ NeutralBenzinga•Nov 10, 2025, 09:15 PM
Cogent Bio surges after late-stage trial data for lead drug
📈 PositiveSeeking Alpha•Nov 10, 2025, 01:09 PM
Cogent Biosciences shares are trading higher after its Phase 3 PEAK study showed a median progression-free survival of 16.5 months for bezuclastinib plus sunitinib; The company plans to submit NDA to FDA for bezuclastinib in intolerant gastrointestinal stromal tumors.
📈 PositiveBenzinga•Nov 10, 2025, 12:48 PM
Trading Halt: Halt status updated at 7:15:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Nov 10, 2025, 12:15 PM
Cogent Biosciences Combination Of Bezuclastinib Plus Sunitinib In Phase 3 PEAK Study Reaches Median Progression Free Survival Of 16.5 Months; Company On Track To Submit New Drug Application To US FDA For Bezuclastinib In Intolerant Gastrointestinal Stromal Tumors
📈 PositiveBenzinga•Nov 10, 2025, 12:11 PM
Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Nov 10, 2025, 11:55 AM
Cogent Biosciences Files For Mixed Shelf Offering, Size Not Disclosed
➖ NeutralBenzinga•Nov 7, 2025, 09:54 PM
HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $21 Price Target
📈 PositiveBenzinga•Nov 4, 2025, 01:09 PM
Cogent Biosciences Announces Updated Preclinical Data From The Co's Potent And Selective Pan KRAS(ON) Inhibitor In A Poster Presentation at the 2025 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics; Says Poster Highlights That CGT1815 Demonstrates Superior Efficacy In KRASG12D And KRASG12V Tumor Growth Inhibition Studies When Compared To RMC-6236.
📈 PositiveBenzinga•Oct 24, 2025, 04:33 PM
JP Morgan Maintains Overweight on Cogent Biosciences, Raises Price Target to $44
📈 PositiveBenzinga•Oct 21, 2025, 11:33 AM
COGT stock has given up its prior gain. Cogent Biosciences shares were trading higher after the company received FDA Breakthrough Therapy Designation for bezuclastinib in non-advanced systemic mastocytosis.
➖ NeutralBenzinga•Oct 20, 2025, 02:02 PM
Frequently Asked Questions about COGT
What is COGT's current stock price?
Cogent Biosciences, Inc. (COGT) is currently trading at $39.55 per share. The stock has moved +4.35% today.
What is the analyst price target for COGT?
The average analyst price target for COGT is $40.40, based on 1 analyst.
What sector is Cogent Biosciences, Inc. in?
Cogent Biosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is COGT's market cap?
Cogent Biosciences, Inc. has a market capitalization of $5.63 billion, making it a mid-cap company.
Does COGT pay dividends?
No, Cogent Biosciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAGIO
Agios Pharmaceuticals, Inc.
$24.46
Mkt Cap: $1.4B
DNLI
Denali Therapeutics Inc.
$16.85
Mkt Cap: $2.5B
ETNB
89bio, Inc.
$14.84
Mkt Cap: $2.2B
GLPG
Galapagos N.V.
$32.36
Mkt Cap: $2.1B
IBRX
ImmunityBio, Inc.
$2.08
Mkt Cap: $2.0B
LQDA
Liquidia Corporation
$34.53
Mkt Cap: $3.0B
OCUL
Ocular Therapeutix, Inc.
$12.56
Mkt Cap: $2.2B
RCUS
Arcus Biosciences, Inc.
$21.98
Mkt Cap: $2.4B
RXRX
Recursion Pharmaceuticals, Inc.
$4.26
Mkt Cap: $1.7B
VRDN
Viridian Therapeutics, Inc.
$31.92
Mkt Cap: $2.6B
Explore stocks similar to COGT for comparison